Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals SafiledCriticalGlaxosmithkline Biologicals Sa
Publication of TR201908114T4publicationCriticalpatent/TR201908114T4/en
fHBP, Neisseria meningitidis?te bir proteindir. Üç fHBP familyası bilinir. Bir fHBP proteininin, familyalar arasında çapraz reaksiyon gösteren antikorlar ortaya çıkarma kabiliyetini arttırmak için fHBP, bir konakçı hayvana uygulandıktan sonra geniş spektrumlu baktrisidal anti-meningokok antikorları ortaya çıkarabilen bir sekansa sahip olacak şekilde seçilir veya değiştirilir.fHBP is a protein in Neisseria meningitidis. Three fHBP families are known. To increase the ability of an fHBP protein to generate antibodies that cross-react between families, fHBP is selected or modified to have a sequence capable of eliciting broad-spectrum bactricidal anti-meningococcal antibodies upon administration to a host animal.
An immunogenic composition comprising: a conjugated pneumococcal capsular saccharide, including depolymerized saccharide of serotype 18c; and meningococcal factor h (fhbp) binding protein antigen, but not including meningococcal membrane vesicles. and method of preparation of the composition.